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Abstract.
BACKGROUND: Determining the optimal treatment for biochemical recurrence (BCR) after radical prostatectomy (RP) is
challenging.
OBJECTIVE:We evaluated the ability of CCP score (a prognostic RNA expression signature) to discriminate between systemic
disease and local recurrence in patients with BCR after RP.
METHODS: Sixty patients with BCR after RP were selected for analysis based on: 1) metastatic disease, 2) non-response to
salvage external beam radiotherapy (EBRT), and 3) durable response to salvage EBRT. CCP scores were generated from the
RNA expression of 46 genes. Logistic regression assessed the association between CCP score and patient group.
RESULTS: Passing CCP scores were generated for 47 patients with complete clinical and pathologic data. CCP score predicted
clinical status when comparing patients with metastatic disease or non-responders to salvage therapy to patients with durable
response (p = 0.006). CCP score remained significantly predictive of clinical status after accounting for time to BCR, PSA level
at BCR, and Gleason score (p = 0.0031).
CONCLUSIONS: Elevated CCP score was associated with increased risk of systemic disease, indicating that CCP score may
be useful in identifying patients with BCR who are most likely to benefit from salvage radiation therapy.
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1. Introduction
Prostate cancer has a highly variable natural his-
tory and accurately assessing the tumor’s aggres-
siveness based on clinical and pathologic features is
challenging. After radical prostatectomy, about 15–
40% of patients will experience biochemical recur-
rence (BCR) [9,11,13,17], which can indicate either
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metastatic disease or local recurrence. Unfortunately,
accurately determining whether a rise in PSA at the
time of BCR is due to an isolated prostatic bed recur-
rence is not possible with the diagnostic tools read-
ily available at this time. Discriminating between these
settings is crucial in the selection of appropriate man-
agement of BCR patients after prostatectomy. Patients
that have metastatic disease are not amenable to cura-
tive local therapy. Conversely, salvage radiotherapy for
local recurrence is an ideal option as it has been shown
to reduce the risk of metastases and improve overall
survival of high-risk patients [16].
Conventional imaging such as bone scan, computed
tomography (CT) and magnetic resonance imaging
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(MRI) lack the sensitivity to detect specific sites of
metastatic disease, especially in patients with PSA less
than 10 mg/ml [7]. Clinical parameters such as time to
BCR, PSA doubling time and Gleason score can help
to stratify risk of metastatic disease, but their predic-
tive power is limited [10,19]. Using an algorithm that
combines Gleason score and time to recurrence, men
can be stratified into risk groups of 82% versus 31% of
being free of metastatic disease 5 years after BCR [13].
Moreover, PSA doubling time requires a period of ob-
servation, which may result in missing the window of
curability with effective salvage radiotherapy.
Variation in the expression of cell cycle progression
(CCP) genes has been shown to predict the behavior
of a diverse array of cancers including breast, lung,
and brain [12,15,20]. Furthermore, the CCP score,
which is a grading system based on measuring the
RNA expression of 31 CCP genes and 15 housekeep-
ing genes, has been associated with prostate cancer
outcomes [1,3–5,8].
We evaluated the ability of the CCP score to dis-
criminate between systemic disease (as defined by ei-
ther metastasis or poor response to salvage radiation)
from local recurrence in the setting of BCR after rad-
ical prostatectomy (indicated by durable response to
salvage radiotherapy) in this pilot study.
2. Materials and methods
After Institutional Review Board approval, a retro-
spective analysis was performed of all patients treated
with radical prostatectomy as primary therapy for
prostate cancer in our institutional prostate cancer
database between 1995 and 2010. We identified all pa-
tients for which we had radical prostatectomy paraf-
fin embedded slides that had a BCR and either de-
veloped metastatic disease or received external beam
salvage radiotherapy with at least 2 years of follow-
up. A cohort of 60 BCR patients was initially identi-
fied. BCR was defined as post-operative PSA greater
than 0.2 mg/ml [2] and patients were categorized into
one of the following three groups: 1) metastatic dis-
ease, 2) non-response to salvage external beam radio-
therapy (EBRT) and 3) durable response to salvage
EBRT. The metastatic disease cohort included patients
with lymph node involvement at the time of surgery
or patients who developed evidence of metastasis on
bone scan, CT or MRI postoperatively, which were ob-
tained when PSA reached 10 ng/ml or when they pre-
sented with symptoms. Imaging was also obtained in
all patients prior to initiation of salvage radiation. Non-
response patients either had no evidence of biochem-
ical response to salvage EBRT or had two consecu-
tive rises in PSA above 0.1 ng/ml after nadir in subse-
quent follow-up. Durable response patients maintained
a PSA < 0.1 ng/ml throughout the study time period
with a minimum of two years of follow-up. Patients
with a history of adjuvant radiation were excluded.
A board certified pathologist (LC) identified tissue
blocks that contained the highest Gleason score which
also corresponded to the tumor lesion with the largest
diameter. The specimens were then analyzed at Myriad
Genetics, Inc. where the selected carcinoma regionwas
macro-dissected, de-paraffinized and RNA extracted
according to previously described methods [5]. CCP
scores were derived from the expression of 31 previ-
ously described CCP genes normalized by the expres-
sion of 15 housekeeper genes. Exclusion criteria in-
cluded insufficient tissue or poor quality RNA result-
ing in non-passing CCP scores [5].
2.1. Statistical methods
A statistical plan was developed prior to data col-
lection and analysis. Logistic regression models were
used to evaluate the association of binary outcomewith
covariates. Effect size was measured by the odds ratio
(OR) per one unit change in a given covariate of in-
terest, with a 95% Wald-type confidence interval (CI).
Profile likelihood CIs were calculated for multivariate
subset analysis in consideration of the small sample
size. Firth’s penalized profile likelihood procedure was
used for univariate tests of contingency tables with an
empty cell. The CCP score was considered continuous
and rounded to one decimal place for all analyses. Us-
ing the D’Amico risk classification, pathologic Glea-
son score was considered a 3-level categorical variable
for logistic regression modeling, but was converted to
integer scoring for calculation of the Pearson correla-
tion coefficient with CCP.
We based all inference on two-sided p-values with
significance level 0.05. Statistical analysis was carried
out at Myriad within the R (version 3.0.1, May 2013;
R Development Core Team) software environment.
3. Results
Prostatectomy specimens from 60 patients were sub-
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Table 1
Clinical characteristics among the 47 eligible patients with passing CCP scores
Variable Outcome*
Metastatic disease N = 22 Non-responders N = 14 Durable response N = 11
CCP score 0.6 (0.1, 1.0) 0.4 (−0.2, 0.6) −0.3 (−0.6, 0.0)
Age at surgery (years) 61 (56, 66) 58 (55, 62) 58 (56, 62)
Pre-surgical PSA (ng/ml) 10.5 (8.0, 15.5) 6.5 (5.0, 9.8) 11.0 (5.5, 17.0)
Pathologic stage
pT2 3 (14%) 4 (29%) 3 (27%)
pT3 19 (86%) 10 (71%) 8 (73%)
Pathologic Gleason score
< 7 2 (9%) 2 (14%) 1 (9%)
7 8 (36%) 7 (50%) 10 (91%)
> 7 12 (55%) 5 (36%) 0 (0%)
Extra-capsular extension 18 (82%) 9 (69%)** 8 (73%)
Seminal vesicle involvement 7 (32%) 3 (21%) 2 (18%)
Positive margins 14 (64%) 5 (36%) 6 (55%)
Lymph node invasion 6 (22%) 0 (0%)† 1 (11%)††
Time from surgery to BCR (months) 12 (4, 24) 12 (1, 22) 0 (0, 21)
PSA at BCR (ng/ml) 0.31 (0.20, 1.0) 0.14 (0.07, 0.42) 0.19 (0.16, 0.26)
*Summary Measures are Median (IQR) for continuous variables and Counts (Column %) for categorical variables. **N = 13, due to 1 patient
missing status for extra-capsular extension. †N = 13, due to 1 patient missing data for lymph node invasion. ††N = 9, due to 2 patients missing
data for lymph node invasion.
Fig. 1. Distribution of CCP scores by outcome group: (A) metastatic diseaseN = 22; (B) non-responders to EBRTN = 14; (C) durable response
to EBRT N = 11.
mitted for CCP gene expression assay. Five patients
were excluded from the study for failing to meeting
clinical eligibility requirements or because of incom-
plete clinical data. Sample blocks from 3 patients con-
tained insufficient tumor for assay and 6 patients did
not have passing CCP scores. Ultimately, 47 patients
were eligible for analysis. Clinical characteristics and
demographics of eligible patients are shown in Table 1.
Pathologic Gleason scores tended to be higher among
patients who had either metastatic disease (55% had
Gleason > 7) or were non-responders to EBRT (36%
had Gleason > 7) compared to patients with durable
response to EBRT. Median follow-up time for the final
cohort was 113 months.
The distributions of CCP score appeared similar be-
tween patients with confirmed metastatic disease and
EBRT non-responders (Fig. 1). All patients in the
durable response group had a CCP score less than 1
and while 73% of the durable responders had a CCP
score of less than 0, only 55% of the non-durable re-
sponders and 18% of the metastatic disease patients
had scores this low.
On univariate logistic regression analysis with bi-
nary outcome of metastatic disease and non-responders
to salvage EBRT versus the durable response group
(Table 2), pathologic Gleason score (p = 0.0073) and
CCP score (p = 0.006) were significantly associated
with outcome. The CCP score had an odds ratio (OR)
of 3.72 for each one-unit change in the CCP score
(95% CI for OR, 1.29, 10.7). There were no significant
interactions between CCP score and any other covari-
ate in predicting outcome (p ≥ 0.08, p = 0.08 specif-
ically for time from surgery to BCR), and the CCP
score was weakly correlated with each of the consid-
ered clinical characteristics.
After adjusting for time from surgery to BCR, PSA
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Table 2
Univariate logistic regression models of binary outcome (metastatic disease or non-responders versus durable response)
Variable Number of Odds ratio 95% confidence P -value Pearson correlation
patients (OR) interval for OR with CCP score
CCP score 47 3.72 (1.29, 10.7) 0.0060 1.00
Age at surgery 47 1.03 (0.93, 1.13) 0.59 0.21
Ln (1 + pre-surgical PSA) 47 0.90 (0.33, 2.43) 0.83 −0.13
Pathologic stage
pT2 10 1.00 (ref) ref 0.59 0.26pT3 37 1.55 (0.33, 7.41)
Pathologic Gleason score‡
<7 5 1.00 (ref) ref
0.0073 0.297 25 0.49 (0.04, 3.19)
>7 17 11.7 (0.53,>100)
Extra-capsular extension* 35 1.27 (0.27, 5.93) 0.77 0.26
Seminal vesicle invasion 12 1.73 (0.32, 9.45) 0.51 0.17
Positive margins 25 0.93 (0.24, 3.61) 0.92 0.20
Lymph node invasion**‡ 7 1.25 (0.21, 13.2) 0.82 0.19
Time from surgery to BCR 47 1.03 (0.98, 1.08) 0.23 −0.05
Ln (1 + PSA at BCR) 47 3.71 (0.31, 44.0) 0.23 0.12
*1 patient missing status for extra-capsular extension. **3 patients missing status for lymph node invasion. ‡OR, 95% CI for OR, and p-value
are based upon Firth’s penalized profile likelihood.
Table 3
Multivariate logistic regression model of binary outcome (metastatic
disease or non-responders versus durable response) with predictors
CCP score, pathologic Gleason score, time to BCR, and PSA at BCR
Variable Odds 95% P -value
ratio confidence
(OR) interval for OR*
CCP score 10.4 (2.05, 90.1) 0.0031
Pathologic Gleason score
< 7 1.00 (ref) ref 0.0016
7 0.08 (0.00, 1.31)
> 7 > 100 (0.23, > 100)
Time from surgery to BCR 1.01 (0.96, 1.08) 0.70
Ln (1+ PSA at BCR) 2.56 (0.16, 135) 0.55
*Confidence intervals fit by profile likelihood.
at BCR, and Gleason score in a multivariate logistic
regression model (Table 3), the CCP score remained
significantly associated with outcome (OR per one unit
change in score = 10.4, 95% CI 2.05, 90.1, p =
0.0031).When comparing patients with metastatic dis-
ease or no response to salvage EBRT to durable re-
sponse, the CCP score remained significantly associ-
ated with outcome, with an OR of 3.64 for a one-unit
change in the CCP score (95% CI for OR, 1.27, 10.5,
p = 0.0056).
4. Discussion
Novel biomarkers have increasingly become a fo-
cus of investigation in prostate cancer as a means of
improving prognostic models and determining more
appropriate treatment decisions. The CCP score was
developed using radical prostatectomy specimens and
has been shown to predict not only BCR after radi-
cal prostatectomy [15,20], but also BCR after primary
EBRT [5] and cancer specific death in conservatively
managed cohorts [4,20]. These studies described the
prognostic utility of CCP scores determined either at
disease diagnosis or immediately after radical therapy.
In this study, we find that the CCP score is po-
tentially valuable in the clinical management of pa-
tients who experience BCR after prostatectomy. The
primary endpoint evaluated was presence of systemic
disease, which was broadly defined as patients with
either metastasis based on imaging studies, or no re-
sponse or nondurable response to salvage radiother-
apy. Previously, Bishoff et al. conducted a subgroup
analysis on the association of CCP scores generated
from prostate biopsy specimens to the development of
metastatic disease. They found that the association be-
tween CCP score and the development of metastasis
was much stronger than the association between CCP
score and the development of BCR. However, as this
was a subgroup analysis, the patient cohort included
only 12 patients with metastatic disease [1].
In our pre-planned analysis comparing patients with
either metastatic disease or salvage EBRT non-res-
ponders to durable responders to salvage, the CCP
score was found to be a significant predictor of out-
come (p = 0.0060), with the risk of systemic dis-
ease increasing 3.72 times for each unit increase of
CCP score. CCP score remained highly significant
even after taking into account time from surgery and
PSA at BCR on multivariate analysis. None of the pa-
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tients with a response to salvage radiotherapy had CCP
scores greater than 1.
Previously published studies have provided evi-
dence that the association between the CCP score and
BCR may be time dependent [4]. In the setting of pri-
mary EBRT, Freedland et al. found that the CCP score
was strongly associated with early recurrences, but was
less strongly associated with late events. The authors
theorized that early BCR was probably a sign of micro-
metastatic disease, whereas later BCR events may be
less indicative of truly aggressive disease and less clin-
ically relevant. The data presented here are consistent
with that conclusion in that high CCP scores appear
to be a harbinger of existing micro-metastatic disease,
and identify patients that are unlikely to benefit from
localized salvage therapy.
Our results validate previous findings of only a weak
correlation between the CCP score and other clini-
cal variables, suggesting that highly proliferative tu-
mors are not easily identifiable based on standard clin-
icopathologic variables. Because CCP genes have a
prominent role in actively replicating cells [18], tumors
with high CCP scores may be particularly responsive
to future cytotoxic therapies [5].
Other gene expression assays have been utilized to
examine post-prostatectomy outcomes and have been
shown to predict biochemical free, metastasis free and
cancer specific survival [14]. For example, Den et
al.compared a genome classifier score between salvage
and adjuvant radiation patients and its ability to predict
clinical metastasis development [6]. However, these
assays have not been shown to predict the likelihood of
responding specifically to salvage local radiation after
prostatectomy as we are examining in this study.
This study is limited by its retrospective nature
and small patient cohort size. Nonetheless, this is
the largest population of prostate cancer patients with
metastatic disease evaluated for the role of CCP score
thus far in this setting. Larger studies are necessary
to validate these results and prove that the score adds
prognostic information after adjusting for clinical vari-
ables.
By delineating the true relationship of CCP score to
disease progression and salvage radiotherapy response,
an additional diagnostic tool will be available in the
treatment of prostate cancer. Ultimately, CCP scores
may predict who would benefit from radiotherapy and
conversely who will not respond, thereby avoiding
the needless side effects and expense from ineffective
treatments.
5. Conclusions
Among patients treated by radical prostatectomy
who develop BCR, CCP score may predict systemic
disease and could be used to help guide subsequent
therapeutic interventions.
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